Reports from Yale University Describe Recent Advances in Eating Disorders (Lisdexamfetamine Maintenance Treatment for Binge-eating Disorder Following Successful Treatments: Randomized Double-blind Placebo-controlled Trial).

A recent study conducted at Yale University examined the efficacy of lisdexamfetamine (LDX) as a maintenance treatment for individuals with binge-eating disorder (BED) and obesity. The study included 61 participants who had responded well to acute treatments with LDX or cognitive-behavioral therapy (CBT) combined with LDX. The results showed that maintenance LDX did not significantly reduce binge-eating episodes but was associated with better outcomes in terms of eating-disorder psychopathology and weight loss compared to a placebo. The study suggests that adults with BED and obesity who respond to acute LDX treatment may benefit from maintenance treatment with LDX. [Extracted from the article]